… in the lives of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine …
… in the lives of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine …
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
… pigmentosa ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across … pigmentosa. ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities and … The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 …
… Results ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across … pigmentosa. ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities, … The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
… in 2019. QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the … N.V. entered into a research collaboration to apply Axiomer ® to fibrosis targets selected by Galapagos. Positive … trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, CEO of ProQR. “We are …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
… not proceed, our primary focus at ProQR remains on our Axiomer ® RNA editing platform,” said Daniel A. de Boer, … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called … in mind. Learn more about ProQR at www.proqr.com . About Axiomer® ProQR is pioneering a next-generation RNA base …